Silverarc Capital Management »

Alnylam Pharmaceuticals shares owned by Silverarc Capital Management

Quarter-by-quarter ownership of Alnylam Pharmaceuticals (ALNY) shares owned by Silverarc Capital Management from 13F filings

Historical chart of Silverarc Capital Management investment in Alnylam Pharmaceuticals

Tip: Access up to 7 years of quarterly data

All positions including Alnylam Pharmaceuticals held by Silverarc Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Alnylam Pharmaceuticals by Silverarc Capital Management

Quarter filed Position value Share count Share price at filing
2023-03-31 $2.8M 14k 200.32
2022-12-31 $8.9M 38k 237.65
2022-09-30 $6.5M 33k 200.15
2022-06-30 $5.8M 40k 145.85

More positions owned by Silverarc Capital Management

ImmunoGen Long Option Calls Call Option
SPRD S&P Biotech ETF Long Option Calls Call Option (XBI)
Akero Therapeutics Long Option Calls Call Option (AKRO)
Mirati Therapeutics Long Option Calls Call Option
Morphic Holding Equities (MORF)
Merus NV Equities (MRUS)
CymaBay Therapeutics Long Option Calls Call Option
Soleno Therapeutics Equities (SLNO)
Intra-Cellular Therapies Equities (ITCI)
Poseida Therapeutics Equities (PSTX)
Krystal Biotech Equities (KRYS)
Mersana Therapeutics Long Option Calls Call Option (MRSN)
KalVista Pharmaceuticals Long Option Calls Call Option (KALV)
Biogen Idec Equities (BIIB)
Urogen Pharma Equities (URGN)

View all positions for Silverarc Capital Management

Top funds holding Alnylam Pharmaceuticals

Vanguard Group
Wellington Management Company
Baillie Gifford & Co
Dodge & Cox
T. Rowe Price Associates
Jpmorgan Chase & Co
Norges Bank Investment Management
venBio Select Advisor
Legal & General Group
Bellevue Group
Bank of New York Mellon
Ubs Global Asset Management Americas
Amundi
Gilder, Gagnon, Howe & Co
Alliancebernstein

View all funds holding Alnylam Pharmaceuticals